BioWorld Asia

Jan. 7, 2004

Celltech Details Phase III Trial Plans For CDP870 In Crohn's

A Phase III program in Crohn's disease is under way to evaluate a compound being developed by Celltech Group plc. (BioWorld International) Read More

Innogenetics Forms Hepatitis C Union With Roche Diagnostics

Researchers Find Gene Similar To BRCA1 In Nematode Worm

SkyePharma Disputing GSK's Royalty Payment For Paxil CR

Xenova Gets US$1.5M From Sale Of KSB's Monoclonal Business

Eirx Seeks To Raise £1M Via Initial Public Offering On AIM

U.S. Navy To Evaluate Inovio's DNA Vaccine Delivery System

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for July 16, 2026.

AI-generated illustration of a neuron with tau protein aggregation

AAIC 2026: Age of amyloid is being joined by time of tau

BioWorld

The Alzheimer’s Association International Conference (AAIC) is the world’s biggest dementia conference. And at the AAIC 2026 meeting, there is big buzz around...

Celia trial: data strong, analysts skeptical

BioWorld

Tuesday brought what was arguably the most anticipated presentation of the 2026 Alzheimer’s Association International Conference when Catherine Mummery, head of...

News in brief

BioWorld Asia

BioWorld Asia briefs for July 14, 2026

Voyager’s gene therapy reduces tau levels in AD models

BioWorld Science

At the Alzheimer’s Association International Conference, researchers from Voyager Therapeutics Inc. presented preclinical efficacy data for VY-1706, a blood-brain...